Glaxo in pandemic flu vaccine move

London-based GlaxoSmithKline said today it was seeking preliminary approval in Europe to market a vaccine against pandemic influenza, which experts fear may be triggered by bird flu.

Since no one can predict the exact form an eventual pandemic flu virus strain would take, the European Medicines Agency has established a “mockup” system that allows companies to start the approval process for core vaccines still under development.